缬沙坦联合美托洛尔治疗充血性心力衰竭疗效观察

目的探讨缬沙坦联合美托洛尔治疗慢性充血性心力衰竭(congestive heart failure,CHF)的临床疗效。方法70例CHF患者用随机单肓对照法分成A组和B组。A组36例给予强心苷及利尿药常规治疗;B组34例在常规治疗基础上加缬沙坦联合美托洛尔,疗程6个月。结果治疗后,B组临床总有效率为85%,A组总有效率56%,两组差别具有统计学意义(P<0.01);两组治疗前后心率、心胸比率、左心室舒张末期内径、左心室收缩末期内径均明显减小、左心室射血分数相比显著增加(P<0.01),未见明显副作用。结论缬沙坦联合美托洛尔治疗CHF疗效优于强心苷及利尿药常规治疗。

Effects of valsartan combined with metoprolol on congestive heart failure

Department of Cardiology,Xuwen Second People's Hospital,Xuwen Guangdong 524100, China Abstract: Objectives To evaluate the therapeutic efficacy of valsartan accompanied with metoprolol in patients with congestive heart failure (CHF). Methods 70 patients with CHF were randomly divided into group A(n=36),who had taken conventional treatment of digitalis and diuretics and group B(n=34), who were given valsartan and metoprolol (betaloc) based on the conventional therapy. The therapeutic period was 6 months. Results After 6 month treatment,the overall effective rate of group B was 84.8%, of group A was 55.5%(P< 0.05). There was a statistically significant difference between two groups. Blood pressure, heart rate, cardiothoracic ratio, LVEDD, LVESD all decreased; LVEF increased significantly (P<0.01)in group B comparing with those in group A. There were few side effects in the group B. Conclusions The therapeutic efficacy of valsartan united with metoprolol in the patients with CHF is satisfactory.